Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ad-CCL21-DC |
Synonyms | |
Therapy Description |
Ad-CCL21-DC is a cancer vaccine comprising dendritic cells engineered to express CCL21, which may enhance antitumor immune response (PMID: 28468947). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ad-CCL21-DC | Autologous dendritic cell-adenovirus CCL21 vaccine | Ad-CCL21-DC is a cancer vaccine comprising dendritic cells engineered to express CCL21, which may enhance antitumor immune response (PMID: 28468947). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03546361 | Phase I | Ad-CCL21-DC Ad-CCL21-DC + Pembrolizumab | CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |